← 프로그램 목록
ADCPhase 2Recruiting

Decitabine and Cedazuridine

Astex PharmaceuticalsInc.

비교

Decitabine and Cedazuridine(Astex Pharmaceuticals, Inc.)은 Acute Myeloid Leukemia 표적 ADC로, Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8 영역에서 개발·상용화 중입니다. 작용기전: in which decitabine acts as a nucleoside metabolic inhibitor promoting DNA hypomethylation and cedazuridine then prevents degradation of decitabine. Phase 2에서 효능·안전성 신호를 검증 중입니다. PFS: 6.1. 차별점: novel CDA inhibitor cedazuridine increases decitabine bioavailability for the treatment of myelodysplastic syndromes.

출처: ClinicalTrials.gov · PubMed · openFDA최근 동기화됨

개요

임상 2026년 7월 12일 (1일 전)PK/독성 2026년 7월 12일 (1일 전)

Acute Myeloid Leukemia

Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8

Recruiting

Technology

구조모아 · StructureMoa에서 구조 검색

adChip and LINE1 sequencing

novel CDA inhibitor cedazuridine increases decitabine bioavailability for the treatment of myelodysplastic syndromes

Mechanism of Action

in which decitabine acts as a nucleoside metabolic inhibitor promoting DNA hypomethylation and cedazuridine then prevents degradation of decitabine

DNA damage sites along with epigenetic factors such as DNA methyltransferase 1 (DNMT1)

임상시험 & 결과

차트 로드 중…

임상 한눈에 보기

  • 50건의 ClinicalTrials.gov 임상 기록
  • Phase·Status 요약은 enrollment 상위 표본 기준입니다
  • 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
  • Phase: Phase 2 · Phase 1, Phase 2 · Phase 3
  • Status: Recruiting · Enrolling by invitation · Completed
  • 주요 endpoint: Timing of treatment Substudy or Tier Advancement Pathway (TAP) assignment · Main Extension Study: Safety: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) · Food Effect Substudy: AUC0-last: Area Under the Plasma Concentration-time Curve From Time Zero to Last Concentration Measured of Decitabine in the Fasted and Fed State · Food Effect Substudy: AUC0-last: Area Under the Plasma Concentration-time Curve From Time Zero to Last Concentration Measured of Cedazuridine in the Fasted and Fed State · Food Effect Substudy: AUC0-last: Area Under the Plasma Concentration-time Curve From Time Zero to Last Concentration Measured of Cedazuridine-epimer in the Fasted and Fed State
  • PFS: 6.1
  • 핵심: Multicenter PK study of ASTX727 versus IV decitabine. Adult participants who were candidates to receive IV decitabine we…

임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.

참고문헌

자주 묻는 질문

Decitabine and Cedazuridine은 어떤 치료제인가요?
Decitabine and Cedazuridine(Astex Pharmaceuticals, Inc.)은 Acute Myeloid Leukemia 표적 ADC로, Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8 영역에서 개발·상용화 중입니다. 데이터는 바이오모아 (BioMoa)에서 ClinicalTrials.gov·openFDA·PubMed 기반으로 정리합니다.
Decitabine and Cedazuridine의 임상 단계는?
Decitabine and Cedazuridine의 현재 단계는 Phase 2입니다.
비슷한 프로그램과 어떻게 비교하나요?
바이오모아 (BioMoa) 비교 페이지에서 PK/PD, 독성, 임상 효능 지표를 나란히 볼 수 있습니다. 동일 타깃·모달리티 프리셋을 함께 참고하세요.